Ataibeckley Inc.
A clinical-stage biopharmaceutical company developing psychedelic-inspired treatments for mental health, including BPL-003, a short-acting nasal spray for hard-to-treat depression. It was born in 2025 from the merger of atai Life Sciences and Beckley Psytech, the latter named after Beckley Park, the centuries-old English estate of the Feilding family. Its lead therapy is a synthetic form of a compound found in toad venom.
Granted 559.2K
Granted 185.2K · Sold 185.2K
Granted 50.0K · Sold 50.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Angermayer Christian +1 co-filerDirector, 10% owner, 10% owner · 3 transactions | — | 55.26M | 559.2K | — | — |
| Craig Kevin JamesChief Medical Officer · 9 transactions | — | 41.5K | 185.2K | — | 185.2K |
| Kochendoerfer GerdChief Operating Officer · 2 transactions | — | 0 | 50.0K | — | 50.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -235.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.